Researchers at the School of Medicine and the Abramson Cancer Center will lead a nationwide trial of anti-cancer drug combinations in patients with advanced kidney cancer, according to a Penn Medicine press release.

Postmenopausal women who are overweight or obese appear to have a greater risk of developing, renal cell carcinoma, a common form of kidney cancer.

Postmenopausal women who are overweight or obese appear to have a greater risk of developing, renal cell carcinoma, a common form of kidney cancer. Studies suggest that a larger waist girth and a history of weight loss and regain further increase this risk.

Postmenopausal women who are overweight or obese appear to have a greater risk of developing, renal cell carcinoma, a common form of kidney cancer, and study findings suggest that a larger waist girth and a history of weight loss and regain further increase this risk.

In the first clinical trial of its kind, researchers at the University of Pennsylvania School of Medicine and the Abramson Cancer Center will lead a nationwide test of anti-cancer drug combinations that target blood vessel growth in patients with advanced kidney cancer.

PHILADELPHIA In the first clinical trial of its kind, researchers at the University of Pennsylvania School of Medicine and the Abramson Cancer Center will lead a nationwide test of anti-cancer drug combinations that target blood vessel growth in patients with advanced kidney cancer.